RE:Nice StartWindy, I think prior to results we were priced at a speculative level based on mediocre results. I would think if we met primary endpoint with -0.6 PAV and met secondary endpoints the stock price should have gone up.
After results the share price was priced like basicially RVX 208 was dead. I saw many comments on this bullboard and other bullboards that they believed RVX was done, and that the drug failed.
Now we know that it is looking more likely that RVX does have a future. But that is not confirmed. Yes the alzheimer and diabetes trials are going ahead. But I guess we will have to wait for September for true confirmation of the future.
I want to go through the Conference Call with a fine tooth comb. But what really has me bullish is the fact that RVX has compounds 15x stronger than 208. Yes it is at very early stages. But this is HUGE. If it can do anymore than 208 and still be safe, we are back in the multi dollar SP, billions of dollars potential. 208 doesnt have that huge upside anymore ($20-40 + royalties), but at minimum it is still valueable to Big Pharma.
I am not sure what a fair value for RVX is at the moment. I do think under $1 is a good deal. But without more good news I dont see $3+ right now, only based on previous trading range.